Short-acting selective and reversible monoamine oxidase A inhibitors, such as pirlindole, are commonly well-tolerated during an overdose. When taken alone, the clinical course is usually well-tolerated and benign.
Deaths from an overdose of this medication have more commonly observed during interactions with tyramine-rich foods tricyclic antidepressants (TCAs), or sympathomimetic drugs, and selective serotonin reuptake inhibitors (SSRIs). The clinical course of adverse effects from these conditions includes agitation, extreme tremor, followed by seizures and hyperthermia. Deaths occurred 3-16 hours after ingestion, after intractable seizure and/or hyperthermia and its sequelae, such as disseminated intravascular coagulation (DIC) and multi-organ failure L1398.
This drug is classified as a reversible inhibitor of monoamine oxidase A enzyme (also known as a RIMA drug). It was developed and is currently used as an antidepressant in Russia. Its chemical structure is similar to metralindole, and it also shares pharmacological properties with this drug.
Pirlindole is a selective, reversible inhibitor of monoamine oxidase (MAO) subtype A (MAO-A) that is approved in several European and non-European countries for the treatment of major depression. The antidepressant efficacy and safety of pirlindole have been demonstrated in numerous studies and, supported by many years of clinical experience in the treatment of depression. Pirlindole's efficacy and safety have also been shown in the treatment of fibromyalgia.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pirlindole. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Pirlindole. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Pirlindole. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pirlindole. |
| Magnesium sulfate | The therapeutic efficacy of Pirlindole can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Pirlindole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Pirlindole may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pirlindole. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Pirlindole. |
| Orphenadrine | Pirlindole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Pirlindole may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Pirlindole. |
| Pramipexole | Pirlindole may increase the sedative activities of Pramipexole. |
| Ropinirole | Pirlindole may increase the sedative activities of Ropinirole. |
| Rotigotine | Pirlindole may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Pirlindole. |
| Sodium oxybate | Pirlindole may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Pirlindole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Thalidomide | Pirlindole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Pirlindole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methylergometrine | The risk or severity of hypertension can be increased when Methylergometrine is combined with Pirlindole. |
| Nicergoline | The risk or severity of hypertension can be increased when Nicergoline is combined with Pirlindole. |
| Phenmetrazine | The risk or severity of hypertension can be increased when Phenmetrazine is combined with Pirlindole. |
| Dutasteride | The risk or severity of hypertension can be increased when Dutasteride is combined with Pirlindole. |
| Propafenone | The risk or severity of hypertension can be increased when Propafenone is combined with Pirlindole. |
| Finasteride | The risk or severity of hypertension can be increased when Finasteride is combined with Pirlindole. |
| Ephedrine | The risk or severity of hypertension can be increased when Ephedrine is combined with Pirlindole. |
| Epicaptopril | The risk or severity of hypertension can be increased when Epicaptopril is combined with Pirlindole. |
| Taxifolin | The risk or severity of hypertension can be increased when Taxifolin is combined with Pirlindole. |
| 1-benzylimidazole | The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Pirlindole. |
| Dronedarone | The risk or severity of hypertension can be increased when Dronedarone is combined with Pirlindole. |
| Amibegron | The risk or severity of hypertension can be increased when Amibegron is combined with Pirlindole. |
| Nylidrin | The risk or severity of hypertension can be increased when Nylidrin is combined with Pirlindole. |
| Solabegron | The risk or severity of hypertension can be increased when Solabegron is combined with Pirlindole. |
| Saralasin | The risk or severity of hypertension can be increased when Saralasin is combined with Pirlindole. |
| Tyramine | The risk or severity of hypertension can be increased when Tyramine is combined with Pirlindole. |
| Adrafinil | The risk or severity of hypertension can be increased when Adrafinil is combined with Pirlindole. |
| Etilefrine | The risk or severity of hypertension can be increased when Etilefrine is combined with Pirlindole. |
| Synephrine | The risk or severity of hypertension can be increased when Synephrine is combined with Pirlindole. |
| Dihydroergocornine | The risk or severity of hypertension can be increased when Pirlindole is combined with Dihydroergocornine. |
| Amitraz | The risk or severity of hypertension can be increased when Pirlindole is combined with Amitraz. |
| Atipamezole | The risk or severity of hypertension can be increased when Pirlindole is combined with Atipamezole. |
| Ractopamine | The risk or severity of hypertension can be increased when Pirlindole is combined with Ractopamine. |
| Anisodamine | The risk or severity of hypertension can be increased when Pirlindole is combined with Anisodamine. |
| Tulobuterol | The risk or severity of hypertension can be increased when Pirlindole is combined with Tulobuterol. |
| Dopexamine | The risk or severity of hypertension can be increased when Pirlindole is combined with Dopexamine. |
| Siponimod | The risk or severity of hypertension can be increased when Pirlindole is combined with Siponimod. |
| Idazoxan | The risk or severity of hypertension can be increased when Pirlindole is combined with Idazoxan. |
| Ebselen | The risk or severity of hypertension can be increased when Pirlindole is combined with Ebselen. |
| Higenamine | The risk or severity of hypertension can be increased when Pirlindole is combined with Higenamine. |
| Reproterol | The risk or severity of hypertension can be increased when Pirlindole is combined with Reproterol. |
| Theodrenaline | The risk or severity of hypertension can be increased when Pirlindole is combined with Theodrenaline. |
| Tramazoline | The risk or severity of hypertension can be increased when Pirlindole is combined with Tramazoline. |
| Octopamine | The risk or severity of hypertension can be increased when Pirlindole is combined with Octopamine. |
| Fenozolone | The risk or severity of hypertension can be increased when Pirlindole is combined with Fenozolone. |
| Dihydroergocristine | The risk or severity of hypertension can be increased when Pirlindole is combined with Dihydroergocristine. |
| Norfenefrine | The risk or severity of hypertension can be increased when Pirlindole is combined with Norfenefrine. |
| Dihydroergocryptine | The risk or severity of hypertension can be increased when Pirlindole is combined with Dihydroergocryptine. |
| Oxyfedrine | The risk or severity of hypertension can be increased when Pirlindole is combined with Oxyfedrine. |
| Terguride | The risk or severity of hypertension can be increased when Pirlindole is combined with Terguride. |
| Xenon | The risk or severity of adverse effects can be increased when Xenon is combined with Pirlindole. |
| Rimiterol | The risk or severity of hypertension can be increased when Pirlindole is combined with Rimiterol. |
| Tretoquinol | The risk or severity of hypertension can be increased when Pirlindole is combined with Tretoquinol. |
| Prenalterol | The risk or severity of hypertension can be increased when Pirlindole is combined with Prenalterol. |
| Xamoterol | The risk or severity of hypertension can be increased when Pirlindole is combined with Xamoterol. |
| Mefenorex | The risk or severity of hypertension can be increased when Pirlindole is combined with Mefenorex. |
| Deoxyepinephrine | The risk or severity of hypertension can be increased when Pirlindole is combined with Deoxyepinephrine. |
| Quinoline Yellow WS | The risk or severity of hypertension can be increased when Pirlindole is combined with Quinoline Yellow WS. |
| Selpercatinib | The risk or severity of hypertension can be increased when Pirlindole is combined with Selpercatinib. |
| Naxitamab | The risk or severity of hypertension can be increased when Pirlindole is combined with Naxitamab. |
| Apraclonidine | Pirlindole may increase the alpha-adrenergic activities of Apraclonidine. |
| Atomoxetine | The risk or severity of adverse effects can be increased when Pirlindole is combined with Atomoxetine. |
| Betahistine | The metabolism of Betahistine can be decreased when combined with Pirlindole. |
| Bezafibrate | Pirlindole may increase the hepatotoxic activities of Bezafibrate. |
| Buprenorphine | Pirlindole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Bupropion | The risk or severity of adverse effects can be increased when Pirlindole is combined with Bupropion. |
| Buspirone | The risk or severity of hypertension can be increased when Pirlindole is combined with Buspirone. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Pirlindole. |
| Cyclobenzaprine | Cyclobenzaprine may increase the serotonergic activities of Pirlindole. |
| Cyproheptadine | Pirlindole may increase the anticholinergic activities of Cyproheptadine. |
| Dextromethorphan | The risk or severity of serotonin syndrome can be increased when Pirlindole is combined with Dextromethorphan. |
| Diethylpropion | The risk or severity of adverse effects can be increased when Pirlindole is combined with Diethylpropion. |
| Domperidone | The risk or severity of QTc prolongation, torsade de pointes, and cardiotoxicity can be increased when Pirlindole is combined with Domperidone. |
| Hydrocodone | Pirlindole may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydromorphone | Pirlindole may increase the serotonergic activities of Hydromorphone. |
| Isometheptene | Pirlindole may increase the sympathomimetic activities of Isometheptene. |
| Levonordefrin | Pirlindole may increase the hypertensive activities of Levonordefrin. |
| Lithium hydroxide | The risk or severity of serotonin syndrome can be increased when Pirlindole is combined with Lithium hydroxide. |
| Lithium citrate | The risk or severity of serotonin syndrome can be increased when Pirlindole is combined with Lithium citrate. |
| Setiptiline | The risk or severity of adverse effects can be increased when Pirlindole is combined with Setiptiline. |
| Aptazapine | The risk or severity of adverse effects can be increased when Pirlindole is combined with Aptazapine. |
| Maprotiline | The risk or severity of adverse effects can be increased when Pirlindole is combined with Maprotiline. |
| Mianserin | The risk or severity of adverse effects can be increased when Pirlindole is combined with Mianserin. |
| Esmirtazapine | The risk or severity of adverse effects can be increased when Pirlindole is combined with Esmirtazapine. |
| Mequitazine | Pirlindole may increase the anticholinergic activities of Mequitazine. |
| Methadone | The risk or severity of serotonin syndrome can be increased when Pirlindole is combined with Methadone. |
| Methyldopa | Pirlindole may decrease the hypotensive activities of Methyldopa. |
| Methylphenidate | Pirlindole may increase the hypertensive activities of Methylphenidate. |
| Dexmethylphenidate | Pirlindole may increase the hypertensive activities of Dexmethylphenidate. |
| Oxycodone | Pirlindole may increase the serotonergic and central nervous system depressant (CNS depressant) activities of Oxycodone. |